Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Editorials |3 September 2013

Expanded Hepatitis C Virus Screening Recommendations Promote Opportunities for Care and Cure Free

Quyen Ngo-Metzger, MD, MPH; John W. Ward, MD; Ronald O. Valdiserri, MD, MPH

Quyen Ngo-Metzger, MD, MPH
From Agency for Healthcare Research and Quality; Rockville, Maryland; Centers for Disease Control and Prevention; Atlanta, Georgia; and U.S. Department of Health and Human Services; Washington, DC.

John W. Ward, MD
From Agency for Healthcare Research and Quality; Rockville, Maryland; Centers for Disease Control and Prevention; Atlanta, Georgia; and U.S. Department of Health and Human Services; Washington, DC.

Ronald O. Valdiserri, MD, MPH
From Agency for Healthcare Research and Quality; Rockville, Maryland; Centers for Disease Control and Prevention; Atlanta, Georgia; and U.S. Department of Health and Human Services; Washington, DC.

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
This article was published at www.annals.org on 25 June 2013.
  • From Agency for Healthcare Research and Quality; Rockville, Maryland; Centers for Disease Control and Prevention; Atlanta, Georgia; and U.S. Department of Health and Human Services; Washington, DC.

    Disclaimer: The views expressed in this publication are solely the opinions of the authors and do not necessarily reflect the official policies of the U.S. Department of Health and Human Services, the Agency for Healthcare Research and Quality, or the Centers for Disease Control and Prevention.

    Acknowledgment: The authors thank Rachel Wilson for her contribution and assistance.

    Potential Conflicts of Interest: None disclosed. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M13-1235.

    Current Author Addresses: Dr. Ngo-Metzger: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850.

    Dr. Ward: Centers for Disease Control and Prevention, Division of Viral Hepatitis, Mail Stop G-37, 1600 Clifton Road NE, Atlanta, GA 30333.

    Dr. Valdiserri: U.S. Department of Health and Human Services, 200 Independence Avenue SW, HHH Building, Room 443-H, Washington, DC 20201.

×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
      1. References
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link
  • CiteULike Link
Chronic hepatitis C virus (HCV) infection is a major health problem in the United States. An estimated 2.7 million to 3.9 million Americans are living with HCV, and transmission continues to occur (1). Hepatitis C is the leading cause of liver transplants in the United States, and without treatment, 15% to 40% of persons living with the virus will develop cirrhosis or cancer. Hepatitis C–related mortality has been steadily increasing, with a 50% rate increase from 1999 to 2007. An estimated 45% to 85% of persons with chronic HCV are unaware that they are infected and thus do not receive needed care and treatment (1). The Centers for Disease Control and Prevention (CDC) estimates that, in the absence of interventions, approximately 1 million HCV-infected persons will die of HCV-related disease. When accompanied by appropriate care and treatment, HCV testing can reduce risk by 70% for hepatocellular carcinoma and by 50% for all-cause mortality (1).
Viral hepatitis was recognized as an important public health problem by the Institute of Medicine in its groundbreaking 2010 report, “Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C” (2). In this report, the institute identified viral hepatitis as an “underappreciated health concern” and provided recommendations to improve hepatitis prevention and control. In response, the U.S. Department of Health and Human Services (HHS) convened a Viral Hepatitis Interagency Working Group to develop an action plan (3) that provides specific HHS agencies with explicit steps to achieve viral hepatitis prevention goals, including increasing the number of persons living with HCV who are aware of their infection status.
The U.S. Preventive Services Task Force (USPSTF) recommendations on HCV screening (4) represent a critical step toward achieving the prevention goals outlined in the HHS action plan. The USPSTF now recommends HCV screening in persons at increased risk and 1-time screening in adults born between 1945 and 1965. These recommendations, which are consistent with those issued by the CDC in 2012 (5), reflect the strength of evidence on the benefits of HCV testing linked to care, treatments, and improved health outcomes. The independently derived yet similar recommendations for HCV testing from the USPSTF and CDC send a clear signal to health care professionals, policymakers, and the public that screening for HCV is effective. We can now focus our efforts on ensuring capacity for the delivery of clinical preventive services that can reduce missed opportunities for HCV diagnosis and linkage to care and treatment.
Risk-based approaches (6) have been most effective in settings providing services for persons with ongoing risk behaviors or health issues indicative of those risks (for example, HIV-infected persons and those receiving dialysis or substance abuse treatment); however, these approaches have been less effective in identifying HCV infection in the general population, particularly in persons infected in the distant past. Among persons living with hepatitis C, approximately 76% were born between 1945 and 1965; persons in this birth cohort (“baby boomers”) accounted for more than 70% of all HCV-associated deaths in 2007 (5). This cohort may have received blood transfusions before the introduction of screening in 1992 or have a history of other risk factors. However, many in this cohort do not or cannot identify any risk factors for their infection. As such, a risk-based approach may miss a substantial proportion of HCV-infected individuals who may remain asymptomatic and unaware of their infection for years.
The expanded screening recommendations are especially important in light of highly effective treatment for HCV. Currently available antiviral agents can elicit a sustained virologic response (virologic clearance or cure) in up to 79% of patients when administered with pegylated interferon and ribavirin, and the benefits of HCV treatment are expected to increase. On the basis of clinical trial data for 2 agents submitted in new drug applications to the U.S. Food and Drug Administration, future treatment regimens will comprise 1 or more antiviral agents (given either with pegylated interferon and ribavirin or as all-oral combinations) and are expected to yield similar or improved rates of viral clearance. These new regimens require shorter durations of treatment (12 to 24 weeks rather than current 24- to 48-week regimens) and are associated with fewer serious adverse events (7).
The promise of improved health outcomes will be realized with successful implementation of both risk-based and birth cohort–based strategies for HCV testing and linkage to care and treatment. Given the USPSTF's grade B designation for HCV testing in baby boomers and others at risk for infection, the 2010 Patient Protection and Affordable Care Act (Affordable Care Act) will facilitate implementation because it requires nongrandfathered, private health plans to cover clinical preventive services given an A or B grade by the USPSTF without cost sharing and provides incentives for Medicaid programs to cover these services. The law will also prohibit insurance companies from declining to sell or renew policies because of such preexisting conditions as viral hepatitis, thus increasing patient access to care and treatment called for in the HHS action plan.
The American Recovery and Reinvestment Act and the Affordable Care Act will improve health infrastructure by fostering the development of new health information technology and health information exchanges. Implementation of standards for electronic medical records can expedite the reporting of HCV-related laboratory and clinical information to public health surveillance systems and close current gaps in screening. As demonstrated by surveillance data, 50% of newly reported HCV cases lack a positive RNA test result (8); electronic medical records can facilitate implementation of recommended HCV testing policies. They also provide an opportunity to monitor the quality of prevention, care, and treatment of viral hepatitis at the public health level.
The comprehensive screening strategies recommended by the USPSTF and CDC create new opportunities for reaching the shared goals of reducing HCV transmission and identifying persons living with HCV and facilitate the receipt of care and treatment. Passage of the Affordable Care Act has created an environment conducive to implementation of risk-based and birth cohort–based strategies. Taken together, the law and newly expanded HCV screening recommendations will help generate the momentum needed to identify millions of Americans previously unaware of their infection status, thus preventing liver disease and deaths attributable to chronic HCV infection.

References

  1. Ward
    JW
    The epidemiology of chronic hepatitis C and one-time hepatitis C virus testing of persons born during 1945 to 1965 in the United States.
    Clin Liver Dis
    2013
    17
    1-11
    .
    PubMed
    CrossRef
    PubMed
  2. Institute of Medicine
    Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C.
    Washington, DC
    National Academies Pr
    2010
  3. U.S. Department of Health and Human Services
    Combating the Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis.
    Washington, DC
    U.S. Department of Health and Human Services
    2011
  4. Moyer
    VA
    U.S. Preventive Services Task Force
    Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement.
    Ann Intern Med
    2013
    159
    349-57
    .
    CrossRef
  5. Smith
    BD
    Morgan
    RL
    Beckett
    GA
    Falck-Ytter
    Y
    Holtzman
    D
    Teo
    CG
    et al
    Centers for Disease Control and Prevention
    Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.
    MMWR Recomm Rep
    2012
    61
    RR-4
    1-32
    .
    PubMed
    PubMed
  6. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention.
    MMWR Recomm Rep
    1998
    47
    RR-19
    1-39
    .
    PubMed
    PubMed
  7. Liang
    TJ
    Ghany
    MG
    Current and future therapies for hepatitis C virus infection.
    N Engl J Med
    2013
    368
    1907-17
    .
    PubMed
    CrossRef
    PubMed
  8. Holmberg
    SD
    Spradling
    PR
    Moorman
    AC
    Denniston
    MM
    Hepatitis C in the United States.
    N Engl J Med
    2013
    368
    1859-61
    .
    PubMed
    CrossRef
    PubMed

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Ngo-Metzger Q, Ward JW, Valdiserri RO. Expanded Hepatitis C Virus Screening Recommendations Promote Opportunities for Care and Cure. Ann Intern Med. 2013;159:364–365. doi: 10.7326/0003-4819-159-5-201309030-00675

Download citation file:

  • RIS (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2018

×
Permissions

Published: Ann Intern Med. 2013;159(5):364-365.

DOI: 10.7326/0003-4819-159-5-201309030-00675

14 Citations

See Also

Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement
View MoreView Less

Related Articles

Curing Hepatitis C Virus Infection: Best Practices From the U.S. Department of Veterans Affairs
Annals of Internal Medicine; 167 (7): 499-504
Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial
Annals of Internal Medicine; 167 (5): 311-318
Hepatitis C Virus Infection Among Reproductive-Aged Women and Children in the United States, 2006 to 2014
Annals of Internal Medicine; 166 (11): 775-782
Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial
Annals of Internal Medicine; 165 (9): 625-634
View MoreView Less

Journal Club

Review: Telaprevir, boceprevir, simeprevir, or sofosbuvir improves response in HCV type 1
Annals of Internal Medicine; 161 (10): JC11
View MoreView Less

Related Point of Care

Hepatitis C Virus
Annals of Internal Medicine; 165 (5): ITC33-ITC48
Hepatitis C
Annals of Internal Medicine; 157 (11): ITC6-1
Hepatitis C
Annals of Internal Medicine; 148 (11): ITC6-1
Hepatitis C Virus (Japanese Version)
Annals of Internal Medicine; 165 (5): JITC33-JITC48
View MoreView Less

Related Topics

Gastroenterology/Hepatology
Infectious Disease
Liver Disease
Prevention/Screening
Viral Hepatitis

Gastroenterology/Hepatology, Infectious Disease, Liver Disease, Prevention/Screening, Viral Hepatitis.

PubMed Articles

Recombinant Flag-tagged E1E2 glycoproteins from three hepatitis C virus genotypes are biologically functional and elicit cross-reactive neutralizing antibodies in mice.
Virology 2018;
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Online First RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards

  • Personae Photography Prize
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2018 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×